SQZ Biotechnologies EBITDA Margin 2020-2023 | SQZ
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for SQZ Biotechnologies (SQZ) over the last 10 years. The current EBITDA margin for SQZ Biotechnologies as of March 31, 2023 is .
| SQZ Biotechnologies EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-12-31 |
$0.02B |
$-0.07B |
-328.57% |
| 2022-09-30 |
$0.02B |
$-0.07B |
-319.05% |
| 2022-06-30 |
$0.02B |
$-0.07B |
-291.30% |
| 2022-03-31 |
$0.03B |
$-0.06B |
-252.00% |
| 2021-12-31 |
$0.03B |
$-0.06B |
-214.81% |
| 2021-09-30 |
$0.02B |
$-0.06B |
-376.47% |
| 2021-06-30 |
$0.02B |
$-0.05B |
-300.00% |
| 2021-03-31 |
$0.02B |
$-0.05B |
-236.84% |
| 2020-12-31 |
$0.02B |
$-0.04B |
-200.00% |
| 2020-06-30 |
$0.02B |
$-0.02B |
-143.75% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.016B |
$0.021B |
|
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
|
